Liquid melevodopa versus standard levodopa in patients with parkinson disease and small intestinal bacterial overgrowth

Clinical Neuropharmacology

Volumn 37, Issue 4, 2014, Pages 91-95

  Fasano, Alfonso ^a   Bove, Francesco ^b   Gabrielli, Maurizio ^b   Ragazzoni, Enzo ^c   Fortuna, Serena ^c   Tortora, Annalisa ^b   Zocco, Maria Assunta ^b   Marconi, Stefano ^d   Gasbarrini, Antonio ^b   Bentivoglio, Anna Rita ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d Department of Pharmacology Catholic University of Sacred Heart ^*  (Italy)

Author keywords

Helicobacter pylori; levodopa; melevodopa; motor fluctuations; parkinson disease; small intestinal bacterial overgrowth

Indexed keywords

CARBIDOPA; CARBIDOPA PLUS LEVODOPA; GLUCOSE; LACTULOSE; LEVODOPA METHYL ESTER; RIFAXIMIN; SIRIO; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; GASTROINTESTINAL AGENT; LEVODOPA; RIFAMYCIN;

AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL OVERGROWTH; BREATH ANALYSIS; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HELICOBACTER INFECTION; HUMAN; INTESTINE FLORA; INTESTINE INFECTION; LATENT PERIOD; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; SMALL INTESTINAL BACTERIAL OVERGROWTH; SMALL INTESTINE; UREA BREATH TEST; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; METABOLISM; MIDDLE AGED; PATHOGENICITY; SEVERITY OF ILLNESS INDEX;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; BREATH TESTS; FEMALE; GASTROINTESTINAL AGENTS; GLUCOSE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LACTULOSE; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RIFAMYCINS; SEVERITY OF ILLNESS INDEX;

EID: 84925365263     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000034     Document Type: Article

References (27)

1. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 2008;23(suppl 3):S497-S508
2. Hoehn MM. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992;10:331-339
3. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19:997-1005
4. Colosimo C, De Michele M. Motor fluctuations in Parkinson's disease: pathophysiology and treatment. Eur J Neurol 1999;6:1-21
5. Djaldetti R, Baron J, Ziv I, et al. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996;46: 1051-1054
6. Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 2006;66:1824-1829
7. Lee WY, Yoon WT, Shin HY, et al. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord 2008;23:1696-1700
8. Gatto M, Fernandez Pardal M, Melero M, et al. L-dopa malabsorption in a parkinsonian patient with Strongyloides stercoralis duodenitis. Clin Neuropharmacol 1994;17:96-98
9. Gabrielli M, Bonazzi P, Scarpellini E, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2011;26:889-892
10. Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013; 28:1241-1249
11. Stocchi F, Barbato L, Bramante L, et al. The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo. Funct Neurol 1994;9:259-264
12. Stocchi F, Fabbri L, Vecsei L, et al. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol 2007;30:18-24
13. Stocchi F, Marconi S. Factors associated with motor fluctuations and dyskinesia in Parkinson disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). Clin Neuropharmacol 2010;33:198-203
14. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39
15. Gasbarrini A, Lauritano EC, Gabrielli M, et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 2007;25:237-240
16. Gasbarrini A, Corazza GR, Gasbarrini G, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther 2009;29(Suppl 1):1-49
17. Khoshini R, Dai SC, Lezcano S, et al. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008;53: 1443-1454
18. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection-a critical review. Aliment Pharmacol Ther 2004;20:1001-1017
19. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25: 2649-2653
20. Defer GL, Widner H, Marie RM, et al. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999;14:572-584
21. Fahn S, Elton R, Committee. MotUD. Recent Developments in Parkinson's Disease. Folorham Park, NJ: Macmillan Health Care Information; 1987
22. Lane RD, Glazer WM, Hansen TE, et al. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis 1985;173:353-357
23. Rondelli I, Acerbi D, Mariotti F, et al. Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1994;653:17-23
24. Steiger MJ, Stocchi F, Carta A, et al. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off " periods in Parkinson's disease. Clin Neuropharmacol 1991;14:241-244
25. Fabbri L, Martignoni E, for the European Study Group. Clinical efficacy of single morning doses of two liquid formulations of levodopa: levodopa/benserazide dispersible and melevodopa/carbidopa effervescent. Neurological Sciences 2003;24:S46
26. Zangaglia R, Stocchi F, Sciarretta M, et al. Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. Clin Neuropharmacol 2010;33:61-66
27. Stocchi F, Zappia M, Dall'Armi V, et al. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. Mov Disord 2010;25:1881-1887